Compare OGEN & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGEN | JAGX |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.9M |
| IPO Year | N/A | N/A |
| Metric | OGEN | JAGX |
|---|---|---|
| Price | $0.88 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 59.0K | ★ 260.1K |
| Earning Date | 11-07-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.45 |
| 52 Week Low | $0.82 | $1.00 |
| 52 Week High | $18.90 | $33.25 |
| Indicator | OGEN | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.68 | 33.77 |
| Support Level | $0.85 | $1.00 |
| Resistance Level | $1.06 | $1.36 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 20.48 | 9.18 |
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.